Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) unit Glenmark Specialty obtained approval from the U.S. Food and Drug Administration for the expanded use of Ryaltris nasal spray, according to a Tuesday Indian bourse filing.
The nasal spray has been approved for the treatment of seasonal allergic rhinitis in pediatric patients older than six years of age and younger than 12.